<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01002118</url>
  </required_header>
  <id_info>
    <org_study_id>200801761</org_study_id>
    <nct_id>NCT01002118</nct_id>
  </id_info>
  <brief_title>Feasibility Study of Omega-3 Fatty Acids in Dialysis Patients</brief_title>
  <official_title>Feasibility of Omega-3 Fatty Acid Supplementation in Adult Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular disease and mortality is the largest comorbidity within the dialysis
      population. Nearly 50% of hemodialysis patients will have congestive heart failure at
      initiation. According to the most recent United States Renal Data System (USRDS), 40% of
      incident dialysis patients will have a cardiovascular event or die within the first 9 months
      of dialysis. It has been postulated that Omega-3 fatty acids could provide beneficial
      cardioprotection in hemodialysis patients. The investigators propose to evaluate Omega-3
      fatty acid doses on cardiovascular parameters in an incident hemodialysis population.
      Initially, this will be a pilot study. Ultimately, the information will be used to adequately
      plan for a larger intervention trial using Omega-3 fatty acids in incident hemodialysis
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular disease and mortality is the largest comorbidity within the dialysis
      population.

      Nearly 50% of hemodialysis patients will have congestive heart failure at initiation.
      According to the most recent USRDS data, 40% of incident dialysis patients will have a
      cardiovascular event or die within the first 9 months of dialysis. The risk of sudden cardiac
      death is estimated to be 6.9% per year of dialysis. Despite this, a recent study found that
      only 8% of dialysis patients received an implantable defibrillator. Numerous studies have
      looked at the acute cardiac effects of hemodialysis. Changes in the QT interval, elevations
      in troponins, increased heart rate variability and heart have all been noted. The mechanisms
      behind these changes and potential preventative measures remain unknown. It has been
      postulated that Omega-3 fatty acids could provide beneficial cardioprotection in hemodialysis
      patients. In nonhemodialysis populations, omega-3 fatty acids (FA) have established
      anti-arrhythmic properties and have been shown to reduce the risk of sudden death and to
      reduce cardiac mortality. In a study of hemodialysis patients, a high dose of omega-3 FA (5
      grams daily) had beneficial effects on electrocardiographic (ECG) surrogate markers of sudden
      death, such as heart rate, heart rate variability, and baroreflex sensitivity. One small
      2-year study of 1.7 grams omega-3 FA in 206 hemodialysis subjects showed a significant
      reduction in myocardial infarction but was not large enough to detect an effect on cardiac or
      total mortality. While these studies are suggestive, the potential therapeutic benefit
      remains unclear and the appropriate dose of Omega-3 in dialysis patients to achieve benefit
      is unknown. Doses of Omega-3 that have shown electrocardiogram benefits were high and require
      6-8 capsules daily. Long-term adherence is likely to be suboptimal with this high pill
      burden. Studies with smaller doses have been of insufficient size to determine any
      cardiovascular benefit. We propose to evaluate two Omega-3 fatty acid doses on cardiovascular
      parameters in a hemodialysis population. Initially, this will be a pilot study. Ultimately,
      the information will be used to adequately plan for a larger intervention trial using Omega-3
      fatty acids in incident hemodialysis patients. I.5 Specify your research question(s), study
      aims or hypotheses (do not indicate &quot;see protocol&quot;) Specific aim 1. Determine recruitment and
      medication adherence rates Recruitment will take place over 6 months and include incident
      hemodialysis patients with a 4 month follow-up. Total expected time for the pilot is one
      year. Participants will be randomized to either moderate dose Omega-3 (4 grams), or 4 tables
      of placebo. Rates of participation, medication adherence and drop out rates will be used to
      plan future trials. HawkIRB
      https://hawkirb.research.uiowa.edu/hawkirb/summary/projects.page?mode=pf&amp;OID=5961841[1/27/201
      0 2:46:08 PM] Specific aim 2. Assess the effectiveness of two Omega-3 fatty acid doses
      compared to placebo on electrocardiographic parameters. All participants will have a
      cardiovascular evaluation at baseline and at end of study. This will include a 48-hour Holter
      monitor, vital signs and blood studies of various cardiovascular risk markers. Specifically,
      we will be assessing heart rate variability, heart rate and QT dispersion.

      Specific aim 3. Assess the side effect profiles of 3.4 g Omega-3 fatty acids to placebo.

      The success of future trials will require subject compliance with therapy. By evaluating the
      side effects of Omega-3, we will be better able to determine the tolerability for future
      studies.

      I Selection of study endpoints. Since this is a feasibility study there will be insufficient
      power to detect changes in physiologic parameters. Omega-3 FA have been shown to beneficially
      influence autonomic function parameters measured by 48-hour Holter we have selected as our
      secondary endpoints changes HRV, heart rate, and QT duration for a dose-ranging study. Blood
      samples will be obtained and properly stored for future studies.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to recruit eligible subjects; no data analyzed
  </why_stopped>
  <start_date type="Actual">January 25, 2008</start_date>
  <completion_date type="Actual">February 23, 2011</completion_date>
  <primary_completion_date type="Actual">February 23, 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine Recruitment Rates</measure>
    <time_frame>4 months</time_frame>
    <description>Determine recruitment by number eligible/number enrolled</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the Effectiveness of Omega-3 Fatty Acid Compared to Placebo on Electrocardiographic Parameters.</measure>
    <time_frame>4 months</time_frame>
    <description>percent of subjects with significant arrhythmia present on Holter electrocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Adherence</measure>
    <time_frame>4 months</time_frame>
    <description>percent of pills taken each month calculated as number of pills taken/number of pills dispensed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 capsules inert oil Placebo each day for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omega-3 Fatty Acid Ethyl Esters</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 capsules Omega-3 Fatty Acid Esters each day for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 Acid Ethyl Esters</intervention_name>
    <description>1 gram capsules Omega-3 Acid Ethyl Esters for a total of 4 grams (4 capsules) per day for 16 weeks</description>
    <arm_group_label>Omega-3 Fatty Acid Ethyl Esters</arm_group_label>
    <other_name>Lovaza Omega-3 Acid Ethyl Esters 4g capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4 capsules each day for 16 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years old

          -  Initiated dialysis in past 3 months

          -  Signed informed consent

          -  Attending University of Iowa dialysis unit for duration of the study

        Exclusion Criteria:

          -  Age &gt;70

          -  Unable to provide consent

          -  Currently taking fish oil supplementation

          -  rhythm other than sinus

          -  implantable cardioverter-defibrillator

          -  pacemaker

          -  myocardial infarction,revascularization or unstable angina in past 3 months

          -  other hospitalization in past 3 months

          -  symptomatic heart failure

          -  known left ventricular ejection fraction &lt; 30%

          -  history of a significant bleeding disorder

          -  severe bleeding episode requiring hospitalization in past 3 months (GI bleed or
             hemorrhagic stroke)

          -  unexplained HgB drop &gt; 2 gm/dl in past 3 months

          -  chronic warfarin or anti-coagulation therapy (such as Lovenox)

          -  pregnant or nursing mothers

          -  allergic to fish, fish oil or fish products

          -  Participation in other trials of investigational products

          -  other characteristics as determined by the investigator that would make sudy
             participation inappropriate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Robinson, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2009</study_first_submitted>
  <study_first_submitted_qc>October 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2009</study_first_posted>
  <results_first_submitted>May 2, 2017</results_first_submitted>
  <results_first_submitted_qc>August 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 9, 2017</results_first_posted>
  <last_update_submitted>August 7, 2017</last_update_submitted>
  <last_update_submitted_qc>August 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Jennifer G. Robinson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>heart rate variability</keyword>
  <keyword>Dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Omega-3 Fatty Acid</title>
          <description>Omega-3 Acid Ethyl Esters: 1 gram capsules for a total of 4 grams (4 capsules) per day for 16 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized Only Patient</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Omega-3 Fatty Acid</title>
          <description>Omega-3 Acid Ethyl Esters: 1 gram capsules for a total of 4 grams (4 capsules) per day for 16 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
        </measure>
        <measure>
          <title>Holter monitor</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Determine Recruitment Rates</title>
        <description>Determine recruitment by number eligible/number enrolled</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omega-3 Fatty Acid</title>
            <description>Omega-3 Acid Ethyl Esters: 1 gram capsules for a total of 4 grams (4 capsules) per day for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Determine Recruitment Rates</title>
          <description>Determine recruitment by number eligible/number enrolled</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess the Effectiveness of Omega-3 Fatty Acid Compared to Placebo on Electrocardiographic Parameters.</title>
        <description>percent of subjects with significant arrhythmia present on Holter electrocardiography</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omega-3 Fatty Acid</title>
            <description>Omega-3 Acid Ethyl Esters: 1 gram capsules for a total of 4 grams (4 capsules) per day for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Assess the Effectiveness of Omega-3 Fatty Acid Compared to Placebo on Electrocardiographic Parameters.</title>
          <description>percent of subjects with significant arrhythmia present on Holter electrocardiography</description>
          <units>percentage of Holter montiors obtained</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medication Adherence</title>
        <description>percent of pills taken each month calculated as number of pills taken/number of pills dispensed</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omega-3 Fatty Acid</title>
            <description>Omega-3 Acid Ethyl Esters: 1 gram capsules for a total of 4 grams (4 capsules) per day for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Medication Adherence</title>
          <description>percent of pills taken each month calculated as number of pills taken/number of pills dispensed</description>
          <units>percentage of pills</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Omega-3 Fatty Acid</title>
          <description>Omega-3 Acid Ethyl Esters: 1 gram capsules for a total of 4 grams (4 capsules) per day for 16 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Robinson</name_or_title>
      <organization>University of Iowa</organization>
      <phone>319-384-1563</phone>
      <email>jennifer-g-robinson@uiowa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

